Unicycive Therapeutics (UNCY) Price & Analysis

Compare

736 Followers

UNCY Stock Chart & Stats

$5.40

-$0.03(-4.01%)

At close: Jan 08 4:00 PM EST

$5.40

-$0.03(-4.01%)

Day’s Range― - ―

52-Week Range$3.71 - $11.00

Previous CloseN/A

Volume1.16M

Average Volume (3M)450.50K

Market Cap

$78.42M

Enterprise Value$36.76M

Total Cash (Recent Filing)$42.70M

Total Debt (Recent Filing)$265.00K

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Mar 26, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding17,661,697

10 Day Avg. Volume334,820

30 Day Avg. Volume450,501

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)7.16

Price to Sales (P/S)0.00

P/FCF Ratio-1.86

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-134.66

Enterprise Value/Ebitda-1.78

Forecast

1Y Price Target

$36.60

Price Target Upside577.78% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityManagement closed the third quarter with cash and cash equivalents of $42.7M, almost doubling the cash reserves from the previous quarter.

Patient SatisfactionThe P2 study of OLC demonstrated strong patient-reported outcomes, with OLC reducing pill burden by 50%, improving adherence, and achieving higher satisfaction and preference compared to prior phosphate binders.

Regulatory ProgressUnicycive plans to resubmit the New Drug Application for Oxylanthanum Carbonate, which could lead to FDA approval.

Bears Say

Commercialization DelayWe have pushed back commercialization estimates for OLC to the second half of 2026, from the first half of 2026, based on the timing of the PDUFA date.

Revenue PerformanceUnicycive reported no revenue for the third quarter, aligning with consensus expectations.

Unicycive Therapeutics News

Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)

“With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the...

13d ago

UNCY

Unicycive Therapeutics sees cash runway into 2027

As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has...

13d ago

UNCY

Ten new option listings on November 5th

New option listings for November 5th include Antares Pharma Inc (AIS), Alpha Tau Medical Ltd (DRTS), Precision BioSciences...

20d ago

AIS

DRTS

Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025

Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of...

26d ago

UNCY

Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Unicycive Therapeutics (UNCY) to $22 from $9 and keeps a...

27d ago

UNCY

Unicycive provides update on meeting with FDA, resubmission of NDA for OLC

Unicycive Therapeutics (UNCY) announced an update from its meeting with the U.S. Food and Drug Administration, FDA, and...

28d ago

UNCY

Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Unicycive Therapeutics and keeping the price target...

10d ago

UNCY

Unicycive Therapeutics Doubles Stock Sale Agreement

Unicycive Therapeutics ( ($UNCY) ) just unveiled an announcement. On November 14, 2025, Unicycive Therapeutics, Inc. amended its...

10d ago

UNCY

Positive Outlook for Unicycive Therapeutics Amidst Promising Developments and Financial Stability

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics and keeping the price target...

12d ago

UNCY

Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Unicycive Therapeutics, with a price target of...

25d ago

UNCY

Unicycive Therapeutics Updates FDA Application for OLC

Unicycive Therapeutics ( ($UNCY) ) just unveiled an update. On October 28, 2025, Unicycive Therapeutics announced an update...

28d ago

UNCY

UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics

A class action lawsuit was filed against Unicycive Therapeutics ($UNCY) by Levi & Korsinsky on August 15, 2025. The plaintiffs (shareholders)...

2M ago

UNCY

Unicycive Therapeutics price target adjusted at Benchmark after reverse split

Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $21 from $3 and keeps a Speculative...

2M ago

UNCY

Unicycive Faces Class Action Over FDA Misleading Claims

Unicycive Therapeutics, Inc., a biopharmaceutical company, is facing a class action lawsuit that could have significant implications for...

3M ago

UNCY

UNCY FAQ

What was Unicycive Therapeutics’s price range in the past 12 months?

Unicycive Therapeutics lowest stock price was $3.71 and its highest was $11.00 in the past 12 months.

What is Unicycive Therapeutics’s market cap?

Unicycive Therapeutics’s market cap is $78.42M.

When is Unicycive Therapeutics’s upcoming earnings report date?

Unicycive Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 121 days.

How were Unicycive Therapeutics’s earnings last quarter?

Unicycive Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.2.

Is Unicycive Therapeutics overvalued?

According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics pay dividends?

Unicycive Therapeutics does not currently pay dividends.

What is Unicycive Therapeutics’s EPS estimate?

Unicycive Therapeutics’s EPS estimate is -0.43.

How many shares outstanding does Unicycive Therapeutics have?

Unicycive Therapeutics has 17,661,697 shares outstanding.

What happened to Unicycive Therapeutics’s price movement after its last earnings report?

Unicycive Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 7.307%.

Which hedge fund is a major shareholder of Unicycive Therapeutics?

Currently, no hedge funds are holding shares in UNCY

Unicycive Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-102.47%

Trailing 12-Months

Asset Growth

-32.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$36.60

▲(577.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","61":"$61","16.75":"$16.75","31.5":"$31.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.75,31.5,46.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,9,13.25,17.5,21.75,26,30.25,34.5,38.75,43,47.25,51.5,55.75,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,7.2,9.65,12.100000000000001,14.55,17,19.450000000000003,21.900000000000002,24.35,26.8,29.25,31.700000000000003,34.150000000000006,{"y":36.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,6,7.25,8.5,9.75,11,12.25,13.5,14.75,16,17.25,18.5,19.75,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >